Real-world Reductions in Migraine and Headache Days for Patients With Migraine Initiating Fremanezumab in Germany

被引：0
|
作者：
Heinze, A. [1 ]
Totev, T. [2 ]
Krasenbaum, L. [3 ]
Terasawa, E. [4 ]
Akcicek, H. [5 ]
Hipp, J. [5 ]
Sun, R. [2 ]
Yim, E. [2 ]
Driessen, M. [5 ]
机构：
[1] Pain Clin Kiel, Migraine & Headache Ctr, Kiel, Germany
[2] Anal Grp Inc, Boston, MA USA
[3] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[4] Anal Grp Inc, New York, NY USA
[5] Teva Pharmaceut, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-075
引用
收藏
页码：419 / 419
页数：1
相关论文
共 50 条
  • [41] Impact of Fremanezumab on the Number of Days with Use of Acute Headache Medications in Episodic Migraine
    Brandes, J.
    Sakai, F.
    Yeung, P. P.
    Blankenbiller, T.
    Grozinski-Wolff, M.
    Yang, R.
    Ma, Y.
    Aycardi, E.
    Bigal, M.
    HEADACHE, 2018, 58 : 103 - 104
  • [42] Reductions in Migraine Frequency With Fremanezumab Treatment in Individuals With Chronic and Episodic Migraine
    Nahas, S. J.
    Ning, X.
    Cohen, J. M.
    Barash, S.
    Campos, V. Ramirez
    Silberstein, S. D.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 169 - 169
  • [43] Reductions in Migraine Frequency With Fremanezumab Treatment in Individuals With Chronic and Episodic Migraine
    Nahas, S. J.
    Ning, X.
    Cohen, J. M.
    Barash, S.
    Campos, V. Ramirez
    Silberstein, S. D.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 114 - 114
  • [44] Fremanezumab for preventive treatment of migraine Functional status on headache-free days
    VanderPluym, Juliana
    Dodick, David W.
    Lipton, Richard B.
    Ma, Yuju
    Loupe, Pippa S.
    Bigal, Marcelo E.
    NEUROLOGY, 2018, 91 (12) : E1152 - E1165
  • [45] Impact of Fremanezumab on the Number of Days with Use of Acute Headache Medications in Chronic Migraine
    Spierings, E. L. H.
    Aycardi, E.
    Yeung, P. P.
    Blankenbiller, T.
    Grozinski-Wolff, M.
    Yang, R.
    Ma, Y.
    Bigal, M.
    HEADACHE, 2018, 58 : 82 - 83
  • [46] Impact of Fremanezumab on the Number of Days with Use of Acute Headache Medications in Chronic Migraine
    Aycardi, Ernesto
    Yeung, Paul P.
    Blankenbiller, Tricia
    Grozinski-Wolff, Melissa
    Yang, Ronghua
    Ma, Yuju
    Spierings, Egilius L. H.
    Bigal, Marcelo E.
    NEUROLOGY, 2018, 90
  • [47] Impact of Fremanezumab on the Number of Days With Use of Acute Headache Medications in Episodic Migraine
    Brandes, Jan
    Sakai, Fumihiko
    Yeung, Paul P.
    Blankenbiller, Tricia
    Grozinski-Wolff, Melissa
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    Bigal, Marcelo E.
    NEUROLOGY, 2018, 90
  • [48] Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series
    Silvestro, Marcello
    Tessitore, Alessandro
    Scotto di Clemente, Fabrizio
    Tedeschi, Gioacchino
    Russo, Antonio
    HEADACHE, 2020, 60 (06): : 1187 - 1195
  • [49] The Impact of Fremanezumab on the Maximum Number of Consecutive Days Without Migraine in Patients with Episodic Migraine
    Dodick, D. W.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 112 - 113
  • [50] Characteristics of Episodic and Chronic Migraine Patients Based on Monthly Headache Days Reported in a Real-world Electronic Medical Records Database
    Foster, S.
    Chen, C.
    Ding, Y.
    Mason, O.
    McGuiness, C.
    Morrow, P.
    Ye, W.
    Wade, R.
    HEADACHE, 2018, 58 : 130 - 131
12345